Fig. 2From: Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer modelTerminal clearance half-time, calculated from last two measured time pointsBack to article page